Vascular Solutions (VASC) 48.99 $VASC Uptrend C
Post# of 273257
Posted On: 09/03/2016 5:03:03 PM
Vascular Solutions (VASC) 48.99 $VASC
Uptrend Call Working As Vascular Solutions Stock Rises 24.1% (VASC)
Comtex SmarTrend(R) - Mon Aug 29, 1:53PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on May 16th, 2016 at $39.32. In approximately 4 months, Vascular Solutions has returned 24.08% as of today's recent price of $48.79.
VASC: 48.99 (+0.53)
Vascular Solutions Up 19.6% Since SmarTrend Uptrend Call (VASC)
Comtex SmarTrend(R) - Thu Aug 11, 1:56PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on May 16th, 2016 at $39.32. In approximately 3 months, Vascular Solutions has returned 19.58% as of today's recent price of $47.02.
VASC: 48.99 (+0.53)
Howard Root to Deliver Keynote at 2016 Dorsey 4D Symposium
BusinessWire - Tue Aug 09, 3:28PM CDT
International law firm Dorsey & Whitney LLP announced today that Howard Root, CEO of Vascular Solutions, will headline the Dorsey 4D Symposium (Dorsey 4DS) in Palo Alto with a keynote address on September 29. The symposium addresses the "4Ds" of the life sciences industry - devices, diagnostics, drugs and digital health. More information is available at dorsey4ds.com.
VASC: 48.99 (+0.53)
Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.26 (-0.07), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zacks.com featured highlights: GCP Applied Technologies, Vascular Solutions, Silver Standard Resources, Energy Recovery and Colony Starwood Homes
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
Zacks.com featured highlights: GCP Applied Technologies, Vascular Solutions, Silver Standard Resources, Energy Recovery and Colony Starwood Homes
SSRI: 12.75 (+0.52), VASC: 48.99 (+0.53), GCP: 29.89 (+0.20), SFR: 31.30 (+0.15), ERII: 12.14 (+0.07)
Vascular Solutions to Present at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 27, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 10th at 8:00am (EDT).
VASC: 48.99 (+0.53)
Vascular Solutions reports 1Q loss
Automated Insights - Mon Apr 25, 3:53PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Monday reported a first-quarter loss of $255,000, after reporting a profit in the same period a year earlier.
VASC: 48.99 (+0.53)
Vascular Solutions Reports First Quarter Results
GlobeNewswire - Mon Apr 25, 3:05PM CDT
-- Revenue increased 14% to $39.4 million, exceeding the top end of guidance
VASC: 48.99 (+0.53)
Vascular Solutions Has Returned 26.1% Since SmarTrend Recommendation (VASC)
Comtex SmarTrend(R) - Mon Apr 18, 1:07PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on February 29th, 2016 at $30.37. In approximately 2 months, Vascular Solutions has returned 26.14% as of today's recent price of $38.31.
VASC: 48.99 (+0.53)
Vascular Solutions, Inc. Issues Recall of Guardian(R) II Hemostasis Valves
GlobeNewswire - Fri Apr 08, 3:05PM CDT
On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
VASC: 48.99 (+0.53)
Vascular Solutions, Inc. to Webcast First Quarter Conference Call
GlobeNewswire - Mon Apr 04, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it will host a live webcast of its first quarter conference call on Monday, April 25th at 3:30pm CDT. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's first quarter results. The company will issue an earnings news release after market close on Monday, April 25th.
VASC: 48.99 (+0.53)
Vascular Solutions to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Fri Apr 01, 3:30PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 15 Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 5:00pm (EDT).
VASC: 48.99 (+0.53)
Vascular Solutions Shares Down 25.0% Since SmarTrend's Sell Call (VASC)
Comtex SmarTrend(R) - Mon Feb 08, 4:19PM CST
SmarTrend identified a Downtrend for Vascular Solutions (NASDAQ:VASC) on January 4th, 2016 at $33.28. In approximately 1 month, Vascular Solutions has returned 24.97% as of today's recent price of $24.97.
VASC: 48.99 (+0.53)
Omnicell Q4 Earnings, Revenues Rise Y/Y; Aesynt Buyout Over
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 11:30AM CST
Omnicell's (OMCL) outperformance on the revenue front is encouraging. However, the company's performance on the bottom-line front remains mixed.
LMAT: 18.35 (+0.59), VASC: 48.99 (+0.53), OMCL: 38.88 (+0.58), HRC: 59.97 (+0.72)
Stryker Eyes Sage Products, Aims to Boost Product Suite
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:25PM CST
Stryker Corp (SYK) recently announced plans to acquire IL-based Sage Products LLC for $2.775 billion.
LMAT: 18.35 (+0.59), VASC: 48.99 (+0.53), SYK: 115.60 (+0.37), MCO: 109.43 (+0.88)
Cepheid Incurs Loss in Q4 as Margins Drop; Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 11:20AM CST
Cepheid (CPHD) ended 2015 on a mixed note.
LMAT: 18.35 (+0.59), CPHD: 34.42 (+0.16), VASC: 48.99 (+0.53), HRC: 59.97 (+0.72)
Uptrend Call Working As Vascular Solutions Stock Rises 24.1% (VASC)
Comtex SmarTrend(R) - Mon Aug 29, 1:53PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on May 16th, 2016 at $39.32. In approximately 4 months, Vascular Solutions has returned 24.08% as of today's recent price of $48.79.
VASC: 48.99 (+0.53)
Vascular Solutions Up 19.6% Since SmarTrend Uptrend Call (VASC)
Comtex SmarTrend(R) - Thu Aug 11, 1:56PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on May 16th, 2016 at $39.32. In approximately 3 months, Vascular Solutions has returned 19.58% as of today's recent price of $47.02.
VASC: 48.99 (+0.53)
Howard Root to Deliver Keynote at 2016 Dorsey 4D Symposium
BusinessWire - Tue Aug 09, 3:28PM CDT
International law firm Dorsey & Whitney LLP announced today that Howard Root, CEO of Vascular Solutions, will headline the Dorsey 4D Symposium (Dorsey 4DS) in Palo Alto with a keynote address on September 29. The symposium addresses the "4Ds" of the life sciences industry - devices, diagnostics, drugs and digital health. More information is available at dorsey4ds.com.
VASC: 48.99 (+0.53)
Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.26 (-0.07), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zacks.com featured highlights: GCP Applied Technologies, Vascular Solutions, Silver Standard Resources, Energy Recovery and Colony Starwood Homes
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
Zacks.com featured highlights: GCP Applied Technologies, Vascular Solutions, Silver Standard Resources, Energy Recovery and Colony Starwood Homes
SSRI: 12.75 (+0.52), VASC: 48.99 (+0.53), GCP: 29.89 (+0.20), SFR: 31.30 (+0.15), ERII: 12.14 (+0.07)
Vascular Solutions to Present at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 27, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 10th at 8:00am (EDT).
VASC: 48.99 (+0.53)
Vascular Solutions reports 1Q loss
Automated Insights - Mon Apr 25, 3:53PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Monday reported a first-quarter loss of $255,000, after reporting a profit in the same period a year earlier.
VASC: 48.99 (+0.53)
Vascular Solutions Reports First Quarter Results
GlobeNewswire - Mon Apr 25, 3:05PM CDT
-- Revenue increased 14% to $39.4 million, exceeding the top end of guidance
VASC: 48.99 (+0.53)
Vascular Solutions Has Returned 26.1% Since SmarTrend Recommendation (VASC)
Comtex SmarTrend(R) - Mon Apr 18, 1:07PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on February 29th, 2016 at $30.37. In approximately 2 months, Vascular Solutions has returned 26.14% as of today's recent price of $38.31.
VASC: 48.99 (+0.53)
Vascular Solutions, Inc. Issues Recall of Guardian(R) II Hemostasis Valves
GlobeNewswire - Fri Apr 08, 3:05PM CDT
On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
VASC: 48.99 (+0.53)
Vascular Solutions, Inc. to Webcast First Quarter Conference Call
GlobeNewswire - Mon Apr 04, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it will host a live webcast of its first quarter conference call on Monday, April 25th at 3:30pm CDT. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's first quarter results. The company will issue an earnings news release after market close on Monday, April 25th.
VASC: 48.99 (+0.53)
Vascular Solutions to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Fri Apr 01, 3:30PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 15 Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 5:00pm (EDT).
VASC: 48.99 (+0.53)
Vascular Solutions Shares Down 25.0% Since SmarTrend's Sell Call (VASC)
Comtex SmarTrend(R) - Mon Feb 08, 4:19PM CST
SmarTrend identified a Downtrend for Vascular Solutions (NASDAQ:VASC) on January 4th, 2016 at $33.28. In approximately 1 month, Vascular Solutions has returned 24.97% as of today's recent price of $24.97.
VASC: 48.99 (+0.53)
Omnicell Q4 Earnings, Revenues Rise Y/Y; Aesynt Buyout Over
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 11:30AM CST
Omnicell's (OMCL) outperformance on the revenue front is encouraging. However, the company's performance on the bottom-line front remains mixed.
LMAT: 18.35 (+0.59), VASC: 48.99 (+0.53), OMCL: 38.88 (+0.58), HRC: 59.97 (+0.72)
Stryker Eyes Sage Products, Aims to Boost Product Suite
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:25PM CST
Stryker Corp (SYK) recently announced plans to acquire IL-based Sage Products LLC for $2.775 billion.
LMAT: 18.35 (+0.59), VASC: 48.99 (+0.53), SYK: 115.60 (+0.37), MCO: 109.43 (+0.88)
Cepheid Incurs Loss in Q4 as Margins Drop; Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 11:20AM CST
Cepheid (CPHD) ended 2015 on a mixed note.
LMAT: 18.35 (+0.59), CPHD: 34.42 (+0.16), VASC: 48.99 (+0.53), HRC: 59.97 (+0.72)
(0)
(0)Scroll down for more posts ▼